# Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

> **NCT00510029** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 72 (estimated)

## Conditions studied

- Arrhythmia

## Interventions

- **DRUG:** GAP-134

## Key facts

- **NCT ID:** NCT00510029
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2008-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00510029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00510029, "Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00510029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*